drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01172 | DB15066 | 416 | 445 | [
"DDInter1004",
"DDInter821"
] | Kanamycin | Givosiran | Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate. | Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a... | Moderate | 1 | [
[
[
416,
24,
445
]
],
[
[
416,
63,
1555
],
[
1555,
24,
445
]
],
[
[
416,
24,
123
],
[
123,
24,
445
]
],
[
[
416,
74,
1132
],
[
1132,
... | [
[
[
"Kanamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Kanamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
... | Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatid... |
DB01211 | DB12332 | 609 | 1,619 | [
"DDInter393",
"DDInter1626"
] | Clarithromycin | Rucaparib | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
609,
24,
1619
]
],
[
[
609,
62,
222
],
[
222,
23,
1619
]
],
[
[
609,
23,
271
],
[
271,
23,
1619
]
],
[
[
609,
25,
1135
],
[
1135,
... | [
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
... | Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mir... |
DB01357 | DB09228 | 890 | 687 | [
"DDInter1160",
"DDInter437"
] | Mestranol | Conestat alfa | The 3-methyl ether of ethinyl estradiol. It must be demethylated to be biologically active. It is used as the estrogen component of many combination ORAL contraceptives. | C1 Esterase Inhibitor (Recombinant) is a recombinant analogue of endogenous complement component-1 esterase inhibitor (rhC1INH), purified from the milk of transgenic rabbits. The primary function of endogenous C1INH is to regulate the activation of the complement and contact system pathways. It does this through inhibi... | Moderate | 1 | [
[
[
890,
24,
687
]
],
[
[
890,
40,
559
],
[
559,
24,
687
]
],
[
[
890,
1,
35
],
[
35,
24,
687
]
],
[
[
890,
25,
350
],
[
350,
25,
... | [
[
[
"Mestranol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conestat alfa"
]
],
[
[
"Mestranol",
"{u} (Compound) resembles {v} (Compound)",
"Estrone"
],
[
"Estrone",
"{u} may cause a moderate int... | Mestranol (Compound) resembles Estrone (Compound) and Estrone may cause a moderate interaction that could exacerbate diseases when taken with Conestat alfa
Mestranol (Compound) resembles Quinestrol (Compound) and Quinestrol may cause a moderate interaction that could exacerbate diseases when taken with Conestat alfa
Me... |
DB00497 | DB14723 | 828 | 159 | [
"DDInter1366",
"DDInter1026"
] | Oxycodone | Larotrectinib | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The f... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
828,
24,
159
]
],
[
[
828,
24,
222
],
[
222,
23,
159
]
],
[
[
828,
24,
98
],
[
98,
24,
159
]
],
[
[
828,
64,
597
],
[
597,
24,
... | [
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatre... |
DB00158 | DB00532 | 356 | 208 | [
"DDInter771",
"DDInter1152"
] | Folic acid | Mephenytoin | Folic acid, also known as folate or Vitamin B9, is a member of the B vitamin family and an essential cofactor for enzymes involved in DNA and RNA synthesis. More specifically, folic acid is required by the body for the synthesis of purines, pyrimidines, and methionine before incorporation into DNA or protein. Folic aci... | Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subuni... | Moderate | 1 | [
[
[
356,
24,
208
]
],
[
[
356,
1,
1147
],
[
1147,
63,
208
]
],
[
[
356,
25,
970
],
[
970,
63,
208
]
],
[
[
356,
35,
663
],
[
663,
63... | [
[
[
"Folic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephenytoin"
]
],
[
[
"Folic acid",
"{u} (Compound) resembles {v} (Compound)",
"Leucovorin"
],
[
"Leucovorin",
"{u} may cause a modera... | Folic acid (Compound) resembles Leucovorin (Compound) and Leucovorin may cause a moderate interaction that could exacerbate diseases when taken with Mephenytoin
Folic acid may lead to a major life threatening interaction when taken with Fluorouracil and Fluorouracil may cause a moderate interaction that could exacerbat... |
DB09065 | DB14575 | 760 | 733 | [
"DDInter424",
"DDInter674"
] | Cobicistat | Eslicarbazepine | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Eslicarbazepine is an anti-epileptic medication available commercially as [eslicarbazepine acetate]. | Moderate | 1 | [
[
[
760,
24,
733
]
],
[
[
760,
62,
1101
],
[
1101,
23,
733
]
],
[
[
760,
63,
168
],
[
168,
23,
733
]
],
[
[
760,
63,
1264
],
[
1264,
... | [
[
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eslicarbazepine"
]
],
[
[
"Cobicistat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[... | Cobicistat may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Eslicarbazepine
Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Borte... |
DB00877 | DB00889 | 629 | 1,133 | [
"DDInter1678",
"DDInter840"
] | Sirolimus | Granisetron | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Moderate | 1 | [
[
[
629,
24,
1133
]
],
[
[
629,
6,
8374
],
[
8374,
45,
1133
]
],
[
[
629,
7,
2652
],
[
2652,
46,
1133
]
],
[
[
629,
18,
4729
],
[
4729,
... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Granisetron"
]
],
[
[
"Sirolimus",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Sirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Granisetron (Compound)
Sirolimus (Compound) upregulates CASP10 (Gene) and CASP10 (Gene) is upregulated by Granisetron (Compound)
Sirolimus (Compound) downregulates EBNA1BP2 (Gene) and EBNA1BP2 (Gene) is downregulated by Granisetron (Compound)
Siroli... |
DB01009 | DB09054 | 935 | 384 | [
"DDInter1009",
"DDInter905"
] | Ketoprofen | Idelalisib | Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
935,
24,
384
]
],
[
[
935,
24,
222
],
[
222,
23,
384
]
],
[
[
935,
40,
307
],
[
307,
23,
384
]
],
[
[
935,
25,
1618
],
[
1618,
2... | [
[
[
"Ketoprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Ketoprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Ketoprofen (Compound) resembles Modafinil (Compound) and Modafinil may cause a minor interaction that can limit ... |
DB01211 | DB09473 | 609 | 884 | [
"DDInter393",
"DDInter918"
] | Clarithromycin | Indium In-111 oxyquinoline | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Indium In 111 oxyquinoline (oxine) is a diagnostic radiopharmaceutical intended for radiolabeling of autologous leukocytes. It is composed of a 3:1 saturated complex of In-111 isotope and oxyquinoline. Indium-111 decays by isomeric transition and electron capture to cadmium-111, emitting a gamma ray that can be detecte... | Moderate | 1 | [
[
[
609,
24,
884
]
],
[
[
609,
24,
423
],
[
423,
24,
884
]
],
[
[
609,
63,
870
],
[
870,
24,
884
]
],
[
[
609,
62,
112
],
[
112,
24,... | [
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indium In-111 oxyquinoline"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cic... | Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Ciclesonide and Ciclesonide may cause a moderate interaction that could exacerbate diseases when taken with Indium In-111 oxyquinoline
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00011 | DB00601 | 1,451 | 453 | [
"DDInter944",
"DDInter1073"
] | Interferon alfa-n1 | Linezolid | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the init... | Moderate | 1 | [
[
[
1451,
24,
453
]
],
[
[
1451,
24,
770
],
[
770,
63,
453
]
],
[
[
1451,
24,
10
],
[
10,
24,
453
]
],
[
[
1451,
63,
491
],
[
491,
2... | [
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linezolid"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"... | Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Linezolid
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Daps... |
DB01017 | DB01253 | 1,669 | 628 | [
"DDInter1224",
"DDInter664"
] | Minocycline | Ergometrine | Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetr... | An ergot alkaloid with uterine and vascular smooth muscle contractile properties. | Moderate | 1 | [
[
[
1669,
24,
628
]
],
[
[
1669,
63,
1131
],
[
1131,
40,
628
]
],
[
[
1669,
40,
964
],
[
964,
24,
628
]
],
[
[
1669,
24,
384
],
[
384,
... | [
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ergometrine"
]
],
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methysergide"
],
... | Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Methysergide and Methysergide (Compound) resembles Ergometrine (Compound)
Minocycline (Compound) resembles Doxycycline (Compound) and Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Er... |
DB00598 | DB01222 | 1,523 | 617 | [
"DDInter1013",
"DDInter246"
] | Labetalol | Budesonide | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Moderate | 1 | [
[
[
1523,
24,
617
]
],
[
[
1523,
63,
251
],
[
251,
1,
617
]
],
[
[
1523,
24,
175
],
[
175,
1,
617
]
],
[
[
1523,
21,
28719
],
[
28719,
... | [
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
]
],
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[
... | Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Budesonide (Compound)
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Budesonide (... |
DB00530 | DB11978 | 1,195 | 124 | [
"DDInter667",
"DDInter822"
] | Erlotinib | Glasdegib | Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
1195,
24,
124
]
],
[
[
1195,
24,
327
],
[
327,
24,
124
]
],
[
[
1195,
63,
79
],
[
79,
24,
124
]
],
[
[
1195,
24,
159
],
[
159,
6... | [
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abametapir"
],
[
... | Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir and Abametapir may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib ... |
DB00585 | DB00630 | 1,127 | 1,485 | [
"DDInter1309",
"DDInter42"
] | Nizatidine | Alendronic acid | A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers. | Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label]. | Minor | 0 | [
[
[
1127,
23,
1485
]
],
[
[
1127,
18,
5615
],
[
5615,
57,
1485
]
],
[
[
1127,
21,
28921
],
[
28921,
60,
1485
]
],
[
[
1127,
1,
1194
],
[
1... | [
[
[
"Nizatidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Alendronic acid"
]
],
[
[
"Nizatidine",
"{u} (Compound) downregulates {v} (Gene)",
"LAGE3"
],
[
"LAGE3",
"{u} (Gene) is downregulated by... | Nizatidine (Compound) downregulates LAGE3 (Gene) and LAGE3 (Gene) is downregulated by Alendronic acid (Compound)
Nizatidine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Alendronic acid (Compound)
Nizatidine (Compound) resembles Ranitidine (Compound) and Ranitidine may cause a minor... |
DB00461 | DB06715 | 598 | 239 | [
"DDInter1254",
"DDInter1500"
] | Nabumetone | Potassium Iodide | Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a de... | Saturated solution of Potassium Iodide (SSKI) is used pharmaceutically for emergency use in patients experiencing acute symptoms of severe hyperthyroidism (also known as thyroid storm or thyrotoxic crisis). SSKI can also be used for radioiodine-contamination emergencies or in preparation of thyrotoxic patients for thyr... | Moderate | 1 | [
[
[
598,
24,
239
]
],
[
[
598,
21,
29196
],
[
29196,
60,
239
]
],
[
[
598,
24,
877
],
[
877,
63,
239
]
],
[
[
598,
24,
1274
],
[
1274,
... | [
[
[
"Nabumetone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Potassium Iodide"
]
],
[
[
"Nabumetone",
"{u} (Compound) causes {v} (Side Effect)",
"Paraesthesia"
],
[
"Paraesthesia",
"{u} (Side Eff... | Nabumetone (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Potassium Iodide (Compound)
Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when take... |
DB00388 | DB01255 | 1,636 | 633 | [
"DDInter1453",
"DDInter1078"
] | Phenylephrine | Lisdexamfetamine | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine, covalently attached to the naturally occurring amino acid L-lysine. Lisdexamfetamine is the first chemically formulated prodrug stimulant and was first approved by the FDA in April 2008. It was also approved... | Moderate | 1 | [
[
[
1636,
24,
633
]
],
[
[
1636,
25,
551
],
[
551,
1,
633
]
],
[
[
1636,
63,
80
],
[
80,
40,
633
]
],
[
[
1636,
24,
1529
],
[
1529,
... | [
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisdexamfetamine"
]
],
[
[
"Phenylephrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenelzine"
],
[
... | Phenylephrine may lead to a major life threatening interaction when taken with Phenelzine and Phenelzine (Compound) resembles Lisdexamfetamine (Compound)
Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Amphetamine and Amphetamine (Compound) resembles Lisdexamfetamine (Compo... |
DB00690 | DB09104 | 1,216 | 286 | [
"DDInter762",
"DDInter1118"
] | Flurazepam | Magnesium hydroxide | A benzodiazepine derivative used mainly as a hypnotic. | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Minor | 0 | [
[
[
1216,
23,
286
]
],
[
[
1216,
1,
481
],
[
481,
23,
286
]
],
[
[
1216,
24,
820
],
[
820,
23,
286
]
],
[
[
1216,
63,
752
],
[
752,
... | [
[
[
"Flurazepam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Flurazepam",
"{u} (Compound) resembles {v} (Compound)",
"Quazepam"
],
[
"Quazepam",
"{u} may cause a mino... | Flurazepam (Compound) resembles Quazepam (Compound) and Quazepam may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can... |
DB01098 | DB01118 | 14 | 33 | [
"DDInter1622",
"DDInter76"
] | Rosuvastatin | Amiodarone | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | Moderate | 1 | [
[
[
14,
24,
33
]
],
[
[
14,
6,
7524
],
[
7524,
45,
33
]
],
[
[
14,
7,
11048
],
[
11048,
46,
33
]
],
[
[
14,
6,
8559
],
[
8559,
46,
... | [
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
]
],
[
[
"Rosuvastatin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compoun... | Rosuvastatin (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Amiodarone (Compound)
Rosuvastatin (Compound) upregulates VAT1 (Gene) and VAT1 (Gene) is upregulated by Amiodarone (Compound)
Rosuvastatin (Compound) binds HMGCR (Gene) and HMGCR (Gene) is upregulated by Amiodarone (Compound)
Rosuvastatin (Compou... |
DB04896 | DB09241 | 901 | 1,629 | [
"DDInter1220",
"DDInter1186"
] | Milnacipran | Methylene blue | Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the a... | Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs ... | Major | 2 | [
[
[
901,
25,
1629
]
],
[
[
901,
63,
1148
],
[
1148,
24,
1629
]
],
[
[
901,
24,
31
],
[
31,
24,
1629
]
],
[
[
901,
64,
73
],
[
73,
25... | [
[
[
"Milnacipran",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Milnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Is... | Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Xylometazol... |
DB11569 | DB14783 | 1,093 | 287 | [
"DDInter1003",
"DDInter574"
] | Ixekizumab | Diroximel fumarate | Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflamma... | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
1093,
24,
287
]
],
[
[
1093,
63,
599
],
[
599,
24,
287
]
],
[
[
1093,
24,
270
],
[
270,
24,
287
]
],
[
[
1093,
64,
1510
],
[
1510,
... | [
[
[
"Ixekizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Ixekizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],... | Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab... |
DB00364 | DB01309 | 417 | 1,254 | [
"DDInter1717",
"DDInter933"
] | Sucralfate | Insulin glulisine | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia. It is considered a _cytoprotective agent_, protect... | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Moderate | 1 | [
[
[
417,
24,
1254
]
],
[
[
417,
24,
1669
],
[
1669,
24,
1254
]
],
[
[
417,
63,
1645
],
[
1645,
24,
1254
]
],
[
[
417,
23,
887
],
[
887,
... | [
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minocycline"
],
... | Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Minocycline and Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Metformin an... |
DB06626 | DB12095 | 263 | 179 | [
"DDInter147",
"DDInter1760"
] | Axitinib | Telotristat ethyl | Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times hi... | Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ... | Moderate | 1 | [
[
[
263,
24,
179
]
],
[
[
263,
24,
214
],
[
214,
24,
179
]
],
[
[
263,
63,
1213
],
[
1213,
24,
179
]
],
[
[
263,
24,
283
],
[
283,
6... | [
[
[
"Axitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Axitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
... | Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and ... |
DB01110 | DB01118 | 86 | 33 | [
"DDInter1209",
"DDInter76"
] | Miconazole | Amiodarone | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-ba... | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | Moderate | 1 | [
[
[
86,
24,
33
]
],
[
[
86,
24,
540
],
[
540,
1,
33
]
],
[
[
86,
6,
7950
],
[
7950,
45,
33
]
],
[
[
86,
6,
8784
],
[
8784,
46,
... | [
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
],
[
... | Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone and Dronedarone (Compound) resembles Amiodarone (Compound)
Miconazole (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Amiodarone (Compound)
Miconazole (Compound) binds CYP51A1 (Gene) and CYP51A1 (Gene) is... |
DB00762 | DB06448 | 613 | 171 | [
"DDInter973",
"DDInter1087"
] | Irinotecan | Lonafarnib | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Major | 2 | [
[
[
613,
25,
171
]
],
[
[
613,
63,
1051
],
[
1051,
24,
171
]
],
[
[
613,
24,
738
],
[
738,
63,
171
]
],
[
[
613,
64,
1064
],
[
1064,
... | [
[
[
"Irinotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lonafarnib"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
],
[
"Ami... | Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Nirapar... |
DB00078 | DB06081 | 1,172 | 1,046 | [
"DDInter898",
"DDInter286"
] | Ibritumomab tiuxetan | Caplacizumab | Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light... | Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU i... | Major | 2 | [
[
[
1172,
25,
1046
]
],
[
[
1172,
23,
539
],
[
539,
62,
1046
]
],
[
[
1172,
24,
1039
],
[
1039,
24,
1046
]
],
[
[
1172,
25,
1171
],
[
1171... | [
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Caplacizumab"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[... | Ibritumomab tiuxetan may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Caplacizumab
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Dexfenf... |
DB01069 | DB15066 | 401 | 445 | [
"DDInter1533",
"DDInter821"
] | Promethazine | Givosiran | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a... | Moderate | 1 | [
[
[
401,
24,
445
]
],
[
[
401,
63,
1555
],
[
1555,
24,
445
]
],
[
[
401,
24,
123
],
[
123,
24,
445
]
],
[
[
401,
64,
702
],
[
702,
2... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
... | Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Ex... |
DB00095 | DB00959 | 66 | 1,486 | [
"DDInter623",
"DDInter1191"
] | Efalizumab | Methylprednisolone | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Moderate | 1 | [
[
[
66,
24,
1486
]
],
[
[
66,
24,
175
],
[
175,
40,
1486
]
],
[
[
66,
24,
167
],
[
167,
1,
1486
]
],
[
[
66,
23,
1193
],
[
1193,
62,... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
... | Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Methylprednisolone (Compound)
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles ... |
DB00836 | DB01069 | 543 | 401 | [
"DDInter1088",
"DDInter1533"
] | Loperamide | Promethazine | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
543,
24,
401
]
],
[
[
543,
63,
146
],
[
146,
24,
401
]
],
[
[
543,
24,
1264
],
[
1264,
63,
401
]
],
[
[
543,
40,
649
],
[
649,
6... | [
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
],
... | Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine and Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Dox... |
DB00405 | DB04843 | 128 | 1,511 | [
"DDInter517",
"DDInter1149"
] | Dexbrompheniramine | Mepenzolate | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Moderate | 1 | [
[
[
128,
24,
1511
]
],
[
[
128,
25,
675
],
[
675,
24,
1511
]
],
[
[
128,
24,
537
],
[
537,
24,
1511
]
],
[
[
128,
63,
352
],
[
352,
... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Dexbrompheniramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextropropoxyphene"
]... | Dexbrompheniramine may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Cyc... |
DB00414 | DB01197 | 590 | 1,603 | [
"DDInter16",
"DDInter292"
] | Acetohexamide | Captopril | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment ... | Moderate | 1 | [
[
[
590,
24,
1603
]
],
[
[
590,
24,
610
],
[
610,
1,
1603
]
],
[
[
590,
23,
1475
],
[
1475,
62,
1603
]
],
[
[
590,
24,
460
],
[
460,
... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Captopril"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enalapril"
],
... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Enalapril and Enalapril (Compound) resembles Captopril (Compound)
Acetohexamide may cause a minor interaction that can limit clinical effects when taken with Sodium citrate and Sodium citrate may cause a minor interaction that... |
DB00834 | DB12245 | 932 | 823 | [
"DDInter1215",
"DDInter1863"
] | Mifepristone | Triclabendazole | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Major | 2 | [
[
[
932,
25,
823
]
],
[
[
932,
23,
112
],
[
112,
23,
823
]
],
[
[
932,
64,
1010
],
[
1010,
24,
823
]
],
[
[
932,
24,
28
],
[
28,
24,... | [
[
[
"Mifepristone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
],
[
[
"Mifepristone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"... | Mifepristone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Mifepristone may lead to a major life threatening interaction when taken with Mefloquine and Mefloquine... |
DB06335 | DB13007 | 761 | 1,060 | [
"DDInter1646",
"DDInter642"
] | Saxagliptin | Enfortumab vedotin | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protea... | Moderate | 1 | [
[
[
761,
24,
1060
]
],
[
[
761,
24,
129
],
[
129,
23,
1060
]
],
[
[
761,
24,
1593
],
[
1593,
24,
1060
]
],
[
[
761,
63,
590
],
[
590,
... | [
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
... | Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Crizotini... |
DB00902 | DB00909 | 104 | 306 | [
"DDInter1168",
"DDInter1971"
] | Methdilazine | Zonisamide | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This... | Major | 2 | [
[
[
104,
25,
306
]
],
[
[
104,
24,
1609
],
[
1609,
63,
306
]
],
[
[
104,
63,
506
],
[
506,
24,
306
]
],
[
[
104,
25,
1311
],
[
1311,
... | [
[
[
"Methdilazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zonisamide"
]
],
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
],
[
"Pen... | Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Zonisamide
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Dextrometho... |
DB00694 | DB08827 | 51 | 990 | [
"DDInter485",
"DDInter1085"
] | Daunorubicin | Lomitapide | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Moderate | 1 | [
[
[
51,
24,
990
]
],
[
[
51,
24,
1080
],
[
1080,
1,
990
]
],
[
[
51,
6,
8374
],
[
8374,
45,
990
]
],
[
[
51,
21,
28701
],
[
28701,
6... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomitapide"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conivaptan"
],
... | Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Conivaptan and Conivaptan (Compound) resembles Lomitapide (Compound)
Daunorubicin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lomitapide (Compound)
Daunorubicin (Compound) causes Discomfort (Side Effect) and Di... |
DB00704 | DB12240 | 267 | 110 | [
"DDInter1263",
"DDInter1485"
] | Naltrexone | Polatuzumab vedotin | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable link... | Moderate | 1 | [
[
[
267,
24,
110
]
],
[
[
267,
63,
467
],
[
467,
24,
110
]
],
[
[
267,
24,
980
],
[
980,
24,
110
]
],
[
[
267,
24,
283
],
[
283,
63,... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
]... | Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Tocilizuma... |
DB08908 | DB12159 | 713 | 12 | [
"DDInter564",
"DDInter609"
] | Dimethyl fumarate | Dupilumab | Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MM... | Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL), that indu... | Moderate | 1 | [
[
[
713,
24,
12
]
],
[
[
713,
63,
599
],
[
599,
24,
12
]
],
[
[
713,
25,
287
],
[
287,
63,
12
]
],
[
[
713,
24,
1129
],
[
1129,
63,
... | [
[
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dupilumab"
]
],
[
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
... | Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Dupilumab
Dimethyl fumarate may lead to a major life threatening interaction when taken with Diroximel fumarate an... |
DB00196 | DB01095 | 600 | 671 | [
"DDInter743",
"DDInter769"
] | Fluconazole | Fluvastatin | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to r... | Moderate | 1 | [
[
[
600,
24,
671
]
],
[
[
600,
23,
14
],
[
14,
63,
671
]
],
[
[
600,
25,
700
],
[
700,
40,
671
]
],
[
[
600,
6,
10215
],
[
10215,
45... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rosuvastatin"
],
[... | Fluconazole may cause a minor interaction that can limit clinical effects when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin
Fluconazole may lead to a major life threatening interaction when taken with Atorvastatin and Atorvastatin (... |
DB12332 | DB15093 | 1,619 | 1,654 | [
"DDInter1626",
"DDInter1698"
] | Rucaparib | Somapacitan | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Moderate | 1 | [
[
[
1619,
24,
1654
]
],
[
[
1619,
63,
608
],
[
608,
23,
1654
]
],
[
[
1619,
63,
10
],
[
10,
24,
1654
]
],
[
[
1619,
62,
1135
],
[
1135,
... | [
[
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
... | Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may ca... |
DB00308 | DB08875 | 347 | 1,618 | [
"DDInter901",
"DDInter262"
] | Ibutilide | Cabozantinib | Ibutilide is a Class III antiarrhythmic agent available in intravenous formulations. It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR). | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
347,
25,
1618
]
],
[
[
347,
23,
112
],
[
112,
23,
1618
]
],
[
[
347,
25,
1662
],
[
1662,
63,
1618
]
],
[
[
347,
24,
480
],
[
480,
... | [
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Ibutilide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronida... | Ibutilide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Ibutilide may lead to a major life threatening interaction when taken with Picosulfuric acid and Picosulfuric... |
DB01396 | DB06791 | 1,482 | 1,446 | [
"DDInter553",
"DDInter1021"
] | Digitoxin | Lanreotide | A cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665) | Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured ... | Moderate | 1 | [
[
[
1482,
24,
1446
]
],
[
[
1482,
63,
1647
],
[
1647,
24,
1446
]
],
[
[
1482,
40,
1252
],
[
1252,
24,
1446
]
],
[
[
1482,
63,
1647
],
[
16... | [
[
[
"Digitoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanreotide"
]
],
[
[
"Digitoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
],
[
... | Digitoxin may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Digitoxin (Compound) resembles Digoxin (Compound) and Digoxin may cause a moderate interaction that could exacerbate ... |
DB00295 | DB00401 | 475 | 84 | [
"DDInter1244",
"DDInter1298"
] | Morphine | Nisoldipine | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contractio... | Moderate | 1 | [
[
[
475,
24,
84
]
],
[
[
475,
24,
854
],
[
854,
1,
84
]
],
[
[
475,
24,
376
],
[
376,
40,
84
]
],
[
[
475,
63,
1428
],
[
1428,
1,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nisoldipine"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nimodipine"
],
[
... | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Nimodipine and Nimodipine (Compound) resembles Nisoldipine (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Amlodipine and Amlodipine (Compound) resembles Nisoldipine (Compound)
Mo... |
DB06674 | DB08826 | 908 | 1,292 | [
"DDInter837",
"DDInter489"
] | Golimumab | Deferiprone | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Major | 2 | [
[
[
908,
25,
1292
]
],
[
[
908,
63,
45
],
[
45,
24,
1292
]
],
[
[
908,
23,
1193
],
[
1193,
63,
1292
]
],
[
[
908,
64,
482
],
[
482,
... | [
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Golimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Didanosine"
],
[
"Didanosine"... | Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Didanosine and Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Deferiprone
Golimumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc ... |
DB00529 | DB06699 | 789 | 774 | [
"DDInter779",
"DDInter493"
] | Foscarnet | Degarelix | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Moderate | 1 | [
[
[
789,
24,
774
]
],
[
[
789,
63,
521
],
[
521,
1,
774
]
],
[
[
789,
21,
28703
],
[
28703,
60,
774
]
],
[
[
789,
23,
112
],
[
112,
... | [
[
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
... | Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Foscarnet (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Degarelix (Compound)
Foscarnet may cause a minor interaction that can lim... |
DB01234 | DB15233 | 1,220 | 1,650 | [
"DDInter513",
"DDInter142"
] | Dexamethasone | Avapritinib | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the trea... | Major | 2 | [
[
[
1220,
25,
1650
]
],
[
[
1220,
24,
1478
],
[
1478,
24,
1650
]
],
[
[
1220,
63,
1101
],
[
1101,
24,
1650
]
],
[
[
1220,
25,
478
],
[
478... | [
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivac... | Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and B... |
DB00365 | DB11837 | 839 | 1,297 | [
"DDInter842",
"DDInter1351"
] | Grepafloxacin | Osilodrostat | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Major | 2 | [
[
[
839,
25,
1297
]
],
[
[
839,
23,
112
],
[
112,
23,
1297
]
],
[
[
839,
25,
401
],
[
401,
24,
1297
]
],
[
[
839,
24,
657
],
[
657,
... | [
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osilodrostat"
]
],
[
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"M... | Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Grepafloxacin may lead to a major life threatening interaction when taken with Promethazine and Promethaz... |
DB00515 | DB13007 | 589 | 1,060 | [
"DDInter387",
"DDInter642"
] | Cisplatin | Enfortumab vedotin | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protea... | Moderate | 1 | [
[
[
589,
24,
1060
]
],
[
[
589,
24,
1593
],
[
1593,
24,
1060
]
],
[
[
589,
63,
58
],
[
58,
24,
1060
]
],
[
[
589,
25,
770
],
[
770,
... | [
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
... | Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and A... |
DB01098 | DB11986 | 14 | 484 | [
"DDInter1622",
"DDInter648"
] | Rosuvastatin | Entrectinib | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
14,
24,
484
]
],
[
[
14,
63,
112
],
[
112,
23,
484
]
],
[
[
14,
25,
466
],
[
466,
62,
484
]
],
[
[
14,
62,
1197
],
[
1197,
24,
... | [
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Rosuvastatin may lead to a major life threatening interaction when taken with Darolutamide and Darolutami... |
DB01169 | DB12161 | 57 | 730 | [
"DDInter120",
"DDInter512"
] | Arsenic trioxide | Deutetrabenazine | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated . The presence of deuterium in deutetrabenazine increases the half-lives ... | Major | 2 | [
[
[
57,
25,
730
]
],
[
[
57,
62,
112
],
[
112,
23,
730
]
],
[
[
57,
64,
322
],
[
322,
24,
730
]
],
[
[
57,
63,
1559
],
[
1559,
24,
... | [
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Arsenic trioxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Arsenic trioxide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Deutetrabenazine
Arsenic trioxide may lead to a major life threatening interaction when taken with Epirubicin and E... |
DB00561 | DB11823 | 1,048 | 858 | [
"DDInter591",
"DDInter673"
] | Doxapram | Esketamine | A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225) | Major depressive disorder (MDD) is a significant cause of disability worldwide and the most common illness preceding suicide.[L5596,A175462] On March 5, 2019, the nasal spray drug, _esketamine_, also known as _Spravato_ (by Janssen Pharmaceuticals), was approved by the FDA for treatment-resistant major depression. Eske... | Major | 2 | [
[
[
1048,
25,
858
]
],
[
[
1048,
1,
1688
],
[
1688,
24,
858
]
],
[
[
1048,
40,
1118
],
[
1118,
24,
858
]
],
[
[
1048,
25,
1629
],
[
1629,
... | [
[
[
"Doxapram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Esketamine"
]
],
[
[
"Doxapram",
"{u} (Compound) resembles {v} (Compound)",
"Diphenoxylate"
],
[
"Diphenoxylate",
"{u} may cause a moderate interaction... | Doxapram (Compound) resembles Diphenoxylate (Compound) and Diphenoxylate may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Doxapram (Compound) resembles Difenoxin (Compound) and Difenoxin may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
... |
DB00247 | DB09065 | 1,131 | 760 | [
"DDInter1194",
"DDInter424"
] | Methysergide | Cobicistat | An ergot derivative that is a congener of lysergic acid diethylamide. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize sero... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Major | 2 | [
[
[
1131,
25,
760
]
],
[
[
1131,
24,
1101
],
[
1101,
23,
760
]
],
[
[
1131,
24,
723
],
[
723,
24,
760
]
],
[
[
1131,
25,
609
],
[
609,
... | [
[
[
"Methysergide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Methysergide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexaro... | Methysergide may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Methysergide may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Apre... |
DB00230 | DB01114 | 784 | 272 | [
"DDInter1516",
"DDInter362"
] | Pregabalin | Chlorpheniramine | Pregabalin is structurally similar to gamma-aminobutyric acid (GABA) - an inhibitory neurotransmitter. It may be used to manage neuropathic pain, postherpetic neuralgia, and fibromyalgia among other conditions. Although as per the FDA Label the mechanism of action has not been definitively characterized, there is evide... | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
784,
24,
272
]
],
[
[
784,
24,
849
],
[
849,
63,
272
]
],
[
[
784,
24,
128
],
[
128,
24,
272
]
],
[
[
784,
21,
28898
],
[
28898,
... | [
[
[
"Pregabalin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Pregabalin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
... | Pregabalin may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Pregabalin may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniram... |
DB08870 | DB11979 | 850 | 1,320 | [
"DDInter228",
"DDInter625"
] | Brentuximab vedotin | Elagolix | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
850,
24,
1320
]
],
[
[
850,
63,
168
],
[
168,
23,
1320
]
],
[
[
850,
63,
79
],
[
79,
24,
1320
]
],
[
[
850,
24,
129
],
[
129,
24... | [
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"... | Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Sorafen... |
DB00477 | DB01218 | 216 | 1,493 | [
"DDInter363",
"DDInter852"
] | Chlorpromazine | Halofantrine | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Major | 2 | [
[
[
216,
25,
1493
]
],
[
[
216,
6,
12523
],
[
12523,
45,
1493
]
],
[
[
216,
7,
5998
],
[
5998,
46,
1493
]
],
[
[
216,
21,
28675
],
[
28675... | [
[
[
"Chlorpromazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
... | Chlorpromazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Halofantrine (Compound)
Chlorpromazine (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Halofantrine (Compound)
Chlorpromazine (Compound) causes Visual impairment (Side Effect) and Visual impairment (Side Effect) is caused... |
DB00603 | DB09043 | 303 | 135 | [
"DDInter1137",
"DDInter36"
] | Medroxyprogesterone acetate | Albiglutide | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prev... | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
303,
24,
135
]
],
[
[
303,
63,
1647
],
[
1647,
23,
135
]
],
[
[
303,
63,
362
],
[
362,
24,
135
]
],
[
[
303,
40,
870
],
[
870,
2... | [
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",... | Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when tak... |
DB09330 | DB11003 | 985 | 748 | [
"DDInter1352",
"DDInter100"
] | Osimertinib | Anthrax vaccine | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsula... | Moderate | 1 | [
[
[
985,
24,
748
]
],
[
[
985,
64,
322
],
[
322,
24,
748
]
],
[
[
985,
62,
168
],
[
168,
24,
748
]
],
[
[
985,
24,
564
],
[
564,
63,... | [
[
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epirubicin"
],
[
"Epi... | Osimertinib may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Osimertinib may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may c... |
DB01406 | DB09330 | 984 | 985 | [
"DDInter472",
"DDInter1352"
] | Danazol | Osimertinib | A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders. | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Moderate | 1 | [
[
[
984,
24,
985
]
],
[
[
984,
24,
1478
],
[
1478,
24,
985
]
],
[
[
984,
63,
663
],
[
663,
24,
985
]
],
[
[
984,
24,
1320
],
[
1320,
... | [
[
[
"Danazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Danazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"I... | Danazol may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Danazol may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexat... |
DB00526 | DB01610 | 1,555 | 248 | [
"DDInter1355",
"DDInter1912"
] | Oxaliplatin | Valganciclovir | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. | Moderate | 1 | [
[
[
1555,
24,
248
]
],
[
[
1555,
24,
1295
],
[
1295,
1,
248
]
],
[
[
1555,
24,
1238
],
[
1238,
24,
248
]
],
[
[
1555,
24,
1480
],
[
1480,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valaciclovir"
],
... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Valaciclovir and Valaciclovir (Compound) resembles Valganciclovir (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Pentostatin and Pentostatin may cause a moderate interactio... |
DB00092 | DB01229 | 58 | 973 | [
"DDInter40",
"DDInter1378"
] | Alefacept | Paclitaxel (protein-bound) | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Moderate | 1 | [
[
[
58,
24,
973
]
],
[
[
58,
24,
310
],
[
310,
63,
973
]
],
[
[
58,
24,
134
],
[
134,
24,
973
]
],
[
[
58,
23,
1461
],
[
1461,
24,
... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Alefacept ... |
DB00344 | DB01064 | 1,302 | 1,148 | [
"DDInter1543",
"DDInter987"
] | Protriptyline | Isoprenaline | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may ... | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Moderate | 1 | [
[
[
1302,
24,
1148
]
],
[
[
1302,
25,
1636
],
[
1636,
24,
1148
]
],
[
[
1302,
24,
480
],
[
480,
24,
1148
]
],
[
[
1302,
21,
28717
],
[
287... | [
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]
],
[
[
"Protriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenylephrine"
],
[
... | Protriptyline may lead to a major life threatening interaction when taken with Phenylephrine and Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formote... |
DB00749 | DB08895 | 59 | 976 | [
"DDInter699",
"DDInter1825"
] | Etodolac | Tofacitinib | Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Moderate | 1 | [
[
[
59,
24,
976
]
],
[
[
59,
63,
1512
],
[
1512,
24,
976
]
],
[
[
59,
24,
1479
],
[
1479,
24,
976
]
],
[
[
59,
63,
1555
],
[
1555,
2... | [
[
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
... | Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and... |
DB00388 | DB00804 | 1,636 | 1,507 | [
"DDInter1453",
"DDInter543"
] | Phenylephrine | Dicyclomine | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may h... | Moderate | 1 | [
[
[
1636,
24,
1507
]
],
[
[
1636,
21,
29231
],
[
29231,
60,
1507
]
],
[
[
1636,
24,
1252
],
[
1252,
23,
1507
]
],
[
[
1636,
25,
551
],
[
5... | [
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
]
],
[
[
"Phenylephrine",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac disorder"
],
[
"Cardiac disorder",
"{u} ... | Phenylephrine (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Dicyclomine (Compound)
Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken... |
DB00564 | DB08912 | 1,236 | 1,040 | [
"DDInter293",
"DDInter462"
] | Carbamazepine | Dabrafenib | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
1236,
24,
1040
]
],
[
[
1236,
6,
4973
],
[
4973,
45,
1040
]
],
[
[
1236,
54,
19201
],
[
19201,
15,
1040
]
],
[
[
1236,
21,
28900
],
[
... | [
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Carbamazepine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compoun... | Carbamazepine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dabrafenib (Compound)
Carbamazepine (Compound) is included by Cytochrome P450 2C19 Inducers (Pharmacologic Class) and Cytochrome P450 2C19 Inducers (Pharmacologic Class) includes Dabrafenib (Compound)
Carbamazepine (Compound) causes Abdominal pain... |
DB06650 | DB10343 | 1,500 | 962 | [
"DDInter1324",
"DDInter160"
] | Ofatumumab | Bacillus calmette-guerin substrain tice live antigen | Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however... | Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of *Mycobacterium bovis* for percutaneous use. It is administered to prevent the development of tuberculosis. | Major | 2 | [
[
[
1500,
25,
962
]
],
[
[
1500,
64,
1057
],
[
1057,
25,
962
]
],
[
[
1500,
24,
270
],
[
270,
64,
962
]
],
[
[
1500,
24,
1362
],
[
1362,
... | [
[
[
"Ofatumumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Ofatumumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
... | Ofatumumab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizum... |
DB00376 | DB09488 | 1,105 | 103 | [
"DDInter1870",
"DDInter23"
] | Trihexyphenidyl | Acrivastine | Trihexyphenidyl is a centrally acting muscarinic antagonist used for treatment of parkinsonism and drug-induced extrapyramidal disorders.[L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity. Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is n... | Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema,... | Moderate | 1 | [
[
[
1105,
24,
103
]
],
[
[
1105,
24,
85
],
[
85,
24,
103
]
],
[
[
1105,
40,
456
],
[
456,
24,
103
]
],
[
[
1105,
63,
999
],
[
999,
2... | [
[
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
],... | Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Trihexyphenidyl (Compound) resembles Biperiden (Compound) and Biperiden may cause a moderate interaction that ... |
DB03404 | DB12887 | 765 | 1,598 | [
"DDInter855",
"DDInter1750"
] | Hemin | Tazemetostat | Hemin (trade name Panhematin) is an iron-containing porphyrin. More specifically, it is protoporphyrin IX containing a ferric iron ion (heme B) with a chloride ligand. | Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020. | Moderate | 1 | [
[
[
765,
24,
1598
]
],
[
[
765,
24,
578
],
[
578,
24,
1598
]
],
[
[
765,
63,
1213
],
[
1213,
24,
1598
]
],
[
[
765,
24,
1046
],
[
1046,
... | [
[
[
"Hemin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
]
],
[
[
"Hemin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Tic... | Hemin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Hemin may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may c... |
DB01101 | DB01125 | 60 | 279 | [
"DDInter285",
"DDInter98"
] | Capecitabine | Anisindione | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | Anisindione is a synthetic anticoagulant and an indanedione derivative. Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagu... | Major | 2 | [
[
[
60,
25,
279
]
],
[
[
60,
63,
328
],
[
328,
24,
279
]
],
[
[
60,
25,
1510
],
[
1510,
63,
279
]
],
[
[
60,
24,
1532
],
[
1532,
63,... | [
[
[
"Capecitabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anisindione"
]
],
[
[
"Capecitabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
],
[
"M... | Capecitabine may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Capecitabine may lead to a major life threatening interaction when taken with Teriflunomide and Terif... |
DB00202 | DB00277 | 190 | 1,031 | [
"DDInter1716",
"DDInter1791"
] | Succinylcholine | Theophylline | Succinylcholine is a depolarizing skeletal muscle relaxant consisting of two molecules of the endogenous neurotransmitter [acetylcholine] (ACh) linked by their acetyl groups. It has been widely used for over 50 years, most commonly in its chloride salt form, as a means of neuromuscular blockade during intubation and su... | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Moderate | 1 | [
[
[
190,
24,
1031
]
],
[
[
190,
24,
746
],
[
746,
40,
1031
]
],
[
[
190,
21,
29339
],
[
29339,
60,
1031
]
],
[
[
190,
23,
1194
],
[
1194,
... | [
[
[
"Succinylcholine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
]
],
[
[
"Succinylcholine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dyphylline"
... | Succinylcholine may cause a moderate interaction that could exacerbate diseases when taken with Dyphylline and Dyphylline (Compound) resembles Theophylline (Compound)
Succinylcholine (Compound) causes Respiratory depression (Side Effect) and Respiratory depression (Side Effect) is caused by Theophylline (Compound)
Succ... |
DB06674 | DB14762 | 908 | 994 | [
"DDInter837",
"DDInter1602"
] | Golimumab | Risankizumab | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease... | Major | 2 | [
[
[
908,
25,
994
]
],
[
[
908,
23,
1114
],
[
1114,
23,
994
]
],
[
[
908,
62,
1461
],
[
1461,
23,
994
]
],
[
[
908,
64,
4
],
[
4,
24,... | [
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Risankizumab"
]
],
[
[
"Golimumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
],
[
"Zinc sulfa... | Golimumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Risankizumab
Golimumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E... |
DB11652 | DB12267 | 1,155 | 1,476 | [
"DDInter1891",
"DDInter233"
] | Tucatinib | Brigatinib | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Major | 2 | [
[
[
1155,
25,
1476
]
],
[
[
1155,
64,
1135
],
[
1135,
23,
1476
]
],
[
[
1155,
63,
168
],
[
168,
23,
1476
]
],
[
[
1155,
64,
629
],
[
629,
... | [
[
[
"Tucatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
],
[
[
"Tucatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may c... | Tucatinib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Tucatinib may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a mino... |
DB00633 | DB01114 | 614 | 272 | [
"DDInter520",
"DDInter362"
] | Dexmedetomidine | Chlorpheniramine | An agonist of receptors, adrenergic alpha-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of dexmedetomidine. | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
614,
24,
272
]
],
[
[
614,
24,
849
],
[
849,
63,
272
]
],
[
[
614,
63,
128
],
[
128,
24,
272
]
],
[
[
614,
6,
12523
],
[
12523,
... | [
[
[
"Dexmedetomidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Dexmedetomidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"... | Dexmedetomidine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Dexmedetomidine may cause a moderate interaction that could exacerbate diseases when taken with Dexbr... |
DB00445 | DB06710 | 322 | 1,546 | [
"DDInter655",
"DDInter1193"
] | Epirubicin | Methyltestosterone | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | A synthetic anabolic steroid used for treating men with testosterone deficiency or similar androgen replacement therapies. Also, has antineoplastic properties and so has been used secondarily in women with advanced breast cancer. Methyltestosterone is a schedule III drug in the US. | Moderate | 1 | [
[
[
322,
24,
1546
]
],
[
[
322,
24,
984
],
[
984,
40,
1546
]
],
[
[
322,
18,
2900
],
[
2900,
46,
1546
]
],
[
[
322,
7,
8224
],
[
8224,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyltestosterone"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danazol"
],
... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Danazol and Danazol (Compound) resembles Methyltestosterone (Compound)
Epirubicin (Compound) downregulates NFKBIA (Gene) and NFKBIA (Gene) is upregulated by Methyltestosterone (Compound)
Epirubicin (Compound) upregulates P4HA2 (G... |
DB00366 | DB00683 | 1,594 | 1,382 | [
"DDInter600",
"DDInter1212"
] | Doxylamine | Midazolam | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazola... | Moderate | 1 | [
[
[
1594,
24,
1382
]
],
[
[
1594,
24,
1216
],
[
1216,
40,
1382
]
],
[
[
1594,
63,
902
],
[
902,
40,
1382
]
],
[
[
1594,
21,
28691
],
[
286... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midazolam"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
],
[
... | Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam (Compound) resembles Midazolam (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resembles Midazolam (Compound)
Doxyla... |
DB00222 | DB06663 | 245 | 1,154 | [
"DDInter825",
"DDInter1398"
] | Glimepiride | Pasireotide | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Moderate | 1 | [
[
[
245,
24,
1154
]
],
[
[
245,
63,
966
],
[
966,
40,
1154
]
],
[
[
245,
21,
28900
],
[
28900,
60,
1154
]
],
[
[
245,
24,
1247
],
[
1247,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Octreotide"
],
[... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Octreotide and Octreotide (Compound) resembles Pasireotide (Compound)
Glimepiride (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Pasireotide (Compound)
Glimepiride may cause a modera... |
DB06772 | DB08895 | 310 | 976 | [
"DDInter259",
"DDInter1825"
] | Cabazitaxel | Tofacitinib | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
310,
25,
976
]
],
[
[
310,
62,
307
],
[
307,
23,
976
]
],
[
[
310,
63,
1461
],
[
1461,
23,
976
]
],
[
[
310,
24,
214
],
[
214,
6... | [
[
[
"Cabazitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Cabazitaxel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil"... | Cabazitaxel may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E ... |
DB00582 | DB12500 | 1,622 | 283 | [
"DDInter1946",
"DDInter714"
] | Voriconazole | Fedratinib | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Major | 2 | [
[
[
1622,
25,
283
]
],
[
[
1622,
23,
466
],
[
466,
62,
283
]
],
[
[
1622,
25,
351
],
[
351,
23,
283
]
],
[
[
1622,
24,
1419
],
[
1419,
... | [
[
[
"Voriconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Voriconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[
"Darolu... | Voriconazole may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Voriconazole may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may ca... |
DB00635 | DB01116 | 1,573 | 601 | [
"DDInter1515",
"DDInter1872"
] | Prednisone | Trimethaphan | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | A nicotinic antagonist that has been used as a ganglionic blocker in hypertension, as an adjunct to anesthesia, and to induce hypotension during surgery. | Moderate | 1 | [
[
[
1573,
24,
601
]
],
[
[
1573,
24,
998
],
[
998,
1,
601
]
],
[
[
1573,
25,
593
],
[
593,
63,
601
]
],
[
[
1573,
1,
891
],
[
891,
2... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethaphan"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
],
... | Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutazone and Phenylbutazone (Compound) resembles Trimethaphan (Compound)
Prednisone may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacer... |
DB09038 | DB09129 | 1,450 | 625 | [
"DDInter636",
"DDInter373"
] | Empagliflozin | Chromic chloride | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Chromic chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN). | Moderate | 1 | [
[
[
1450,
24,
625
]
],
[
[
1450,
63,
473
],
[
473,
24,
625
]
],
[
[
1450,
24,
1296
],
[
1296,
63,
625
]
],
[
[
1450,
63,
473
],
[
473,
... | [
[
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromic chloride"
]
],
[
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
... | Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Chromic chloride
Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Insulin... |
DB00795 | DB01174 | 50 | 697 | [
"DDInter1725",
"DDInter1442"
] | Sulfasalazine | Phenobarbital | Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down i... | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Minor | 0 | [
[
[
50,
23,
697
]
],
[
[
50,
63,
362
],
[
362,
1,
697
]
],
[
[
50,
6,
5912
],
[
5912,
45,
697
]
],
[
[
50,
63,
1512
],
[
1512,
23,
... | [
[
[
"Sulfasalazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phenobarbital"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
... | Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Phenobarbital (Compound)
Sulfasalazine (Compound) binds ABCC2 (Gene) and ABCC2 (Gene) is bound by Phenobarbital (Compound)
Sulfasalazine may cause a moderate interaction that could ... |
DB06292 | DB09098 | 549 | 98 | [
"DDInter474",
"DDInter1700"
] | Dapagliflozin | Somatrem | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
549,
24,
98
]
],
[
[
549,
63,
168
],
[
168,
23,
98
]
],
[
[
549,
63,
336
],
[
336,
24,
98
]
],
[
[
549,
62,
79
],
[
79,
24,
... | [
[
[
"Dapagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Dapagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
... | Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somatrem
Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nife... |
DB00738 | DB06595 | 485 | 1,491 | [
"DDInter1420",
"DDInter1214"
] | Pentamidine | Midostaurin | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
485,
24,
1491
]
],
[
[
485,
23,
112
],
[
112,
23,
1491
]
],
[
[
485,
24,
761
],
[
761,
24,
1491
]
],
[
[
485,
63,
888
],
[
888,
... | [
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Pentamidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Pentamidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and ... |
DB11978 | DB12267 | 124 | 1,476 | [
"DDInter822",
"DDInter233"
] | Glasdegib | Brigatinib | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
124,
24,
1476
]
],
[
[
124,
63,
1612
],
[
1612,
23,
1476
]
],
[
[
124,
62,
1135
],
[
1135,
23,
1476
]
],
[
[
124,
63,
629
],
[
629,
... | [
[
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
... | Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Glasdegib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol m... |
DB00741 | DB10583 | 167 | 949 | [
"DDInter885",
"DDInter415"
] | Hydrocortisone | Clostridium tetani toxoid antigen (formaldehyde inactivated) | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Clostridium tetani toxoid antigen (formaldehyde inactivated) is a vaccine for intramuscular injection. It is used for active immunization of children 7 years of age or older, and adults, for prevention of tetanus. The toxoid in the Clostridium tetani culture is grown and detoxified followed by purification via ammonium... | Moderate | 1 | [
[
[
167,
24,
949
]
],
[
[
167,
63,
589
],
[
589,
24,
949
]
],
[
[
167,
25,
1377
],
[
1377,
24,
949
]
],
[
[
167,
25,
1259
],
[
1259,
... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate disease... | Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Hydrocortisone may lead to a major life threatening interact... |
DB00774 | DB11057 | 1,577 | 720 | [
"DDInter889",
"DDInter1223"
] | Hydroflumethiazide | Mineral oil | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822) | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Moderate | 1 | [
[
[
1577,
24,
720
]
],
[
[
1577,
63,
175
],
[
175,
24,
720
]
],
[
[
1577,
1,
323
],
[
323,
24,
720
]
],
[
[
1577,
24,
1486
],
[
1486,
... | [
[
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinol... | Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Hydroflumethiazide (Compound) resembles Bendroflumethiazide (Compound) and Bendroflumethiazide ma... |
DB00295 | DB01036 | 475 | 211 | [
"DDInter1244",
"DDInter1832"
] | Morphine | Tolterodine | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors. | Moderate | 1 | [
[
[
475,
24,
211
]
],
[
[
475,
25,
358
],
[
358,
40,
211
]
],
[
[
475,
24,
573
],
[
573,
40,
211
]
],
[
[
475,
24,
128
],
[
128,
24,... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
]
],
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Orphenadrine"
],
[
"Orphenadrin... | Morphine may lead to a major life threatening interaction when taken with Orphenadrine and Orphenadrine (Compound) resembles Tolterodine (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Fesoterodine and Fesoterodine (Compound) resembles Tolterodine (Compound)
Morphine ... |
DB00247 | DB08912 | 1,131 | 1,040 | [
"DDInter1194",
"DDInter462"
] | Methysergide | Dabrafenib | An ergot derivative that is a congener of lysergic acid diethylamide. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize sero... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
1131,
24,
1040
]
],
[
[
1131,
21,
28900
],
[
28900,
60,
1040
]
],
[
[
1131,
24,
1101
],
[
1101,
23,
1040
]
],
[
[
1131,
24,
478
],
[
4... | [
[
[
"Methysergide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Methysergide",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side E... | Methysergide (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dabrafenib (Compound)
Methysergide may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken ... |
DB01232 | DB09049 | 1,327 | 1,135 | [
"DDInter1640",
"DDInter1261"
] | Saquinavir | Naloxegol | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Major | 2 | [
[
[
1327,
25,
1135
]
],
[
[
1327,
25,
1406
],
[
1406,
62,
1135
]
],
[
[
1327,
64,
1424
],
[
1424,
23,
1135
]
],
[
[
1327,
25,
1069
],
[
10... | [
[
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
]
],
[
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
],
[
"Neratinib",
"{u} may ... | Saquinavir may lead to a major life threatening interaction when taken with Neratinib and Neratinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Saquinavir may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a minor interaction that c... |
DB00277 | DB11569 | 1,031 | 1,093 | [
"DDInter1791",
"DDInter1003"
] | Theophylline | Ixekizumab | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflamma... | Moderate | 1 | [
[
[
1031,
24,
1093
]
],
[
[
1031,
24,
1683
],
[
1683,
24,
1093
]
],
[
[
1031,
23,
1382
],
[
1382,
24,
1093
]
],
[
[
1031,
25,
143
],
[
143... | [
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
... | Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Theophylline may cause a minor interaction that can limit clinical effects when taken with Midazolam and Mid... |
DB00900 | DB01041 | 45 | 770 | [
"DDInter544",
"DDInter1789"
] | Didanosine | Thalidomide | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-termi... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
45,
24,
770
]
],
[
[
45,
21,
29742
],
[
29742,
60,
770
]
],
[
[
45,
63,
168
],
[
168,
24,
770
]
],
[
[
45,
24,
850
],
[
850,
63,... | [
[
[
"Didanosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Didanosine",
"{u} (Compound) causes {v} (Side Effect)",
"Hepatomegaly"
],
[
"Hepatomegaly",
"{u} (Side Effect) ... | Didanosine (Compound) causes Hepatomegaly (Side Effect) and Hepatomegaly (Side Effect) is caused by Thalidomide (Compound)
Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB08916 | DB12332 | 26 | 1,619 | [
"DDInter32",
"DDInter1626"
] | Afatinib | Rucaparib | Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal grow... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
26,
24,
1619
]
],
[
[
26,
63,
888
],
[
888,
24,
1619
]
],
[
[
26,
24,
1313
],
[
1313,
24,
1619
]
],
[
[
26,
24,
1180
],
[
1180,
... | [
[
[
"Afatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Afatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
"T... | Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant and Suvorexant ma... |
DB00039 | DB01181 | 1,253 | 1,532 | [
"DDInter1380",
"DDInter906"
] | Palifermin | Ifosfamide | Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004. | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
1253,
24,
1532
]
],
[
[
1253,
24,
1648
],
[
1648,
24,
1532
]
],
[
[
1253,
24,
1330
],
[
1330,
63,
1532
]
],
[
[
1253,
24,
1064
],
[
10... | [
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
... | Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab and Naxit... |
DB00489 | DB01124 | 17 | 1,411 | [
"DDInter1704",
"DDInter1828"
] | Sotalol | Tolbutamide | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
17,
24,
1411
]
],
[
[
17,
24,
959
],
[
959,
40,
1411
]
],
[
[
17,
63,
245
],
[
245,
40,
1411
]
],
[
[
17,
21,
28828
],
[
28828,
... | [
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"G... | Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Compound)
Sota... |
DB04845 | DB11601 | 309 | 1,270 | [
"DDInter1001",
"DDInter1889"
] | Ixabepilone | Tuberculin purified protein derivative | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Moderate | 1 | [
[
[
309,
24,
1270
]
],
[
[
309,
24,
350
],
[
350,
24,
1270
]
],
[
[
309,
63,
869
],
[
869,
24,
1270
]
],
[
[
309,
64,
1064
],
[
1064,
... | [
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Ixabepilone may cause a moderate interaction that could exacerbate diseases when ... |
DB00342 | DB06448 | 1,181 | 171 | [
"DDInter1770",
"DDInter1087"
] | Terfenadine | Lonafarnib | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Moderate | 1 | [
[
[
1181,
24,
171
]
],
[
[
1181,
24,
888
],
[
888,
24,
171
]
],
[
[
1181,
23,
112
],
[
112,
24,
171
]
],
[
[
1181,
25,
1424
],
[
1424,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
... | Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Terfenadine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metro... |
DB01254 | DB10795 | 1,213 | 221 | [
"DDInter484",
"DDInter1486"
] | Dasatinib | Poliovirus type 1 antigen (formaldehyde inactivated) | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were grown from a c... | Moderate | 1 | [
[
[
1213,
24,
221
]
],
[
[
1213,
24,
36
],
[
36,
24,
221
]
],
[
[
1213,
64,
581
],
[
581,
24,
221
]
],
[
[
1213,
63,
599
],
[
599,
2... | [
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with ... | Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Dasatinib may lead to a major life threatening interaction when taken with ... |
DB01611 | DB06589 | 1,487 | 1,250 | [
"DDInter893",
"DDInter1400"
] | Hydroxychloroquine | Pazopanib | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Major | 2 | [
[
[
1487,
25,
1250
]
],
[
[
1487,
6,
12523
],
[
12523,
45,
1250
]
],
[
[
1487,
18,
9853
],
[
9853,
57,
1250
]
],
[
[
1487,
21,
28658
],
[
... | [
[
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
]
],
[
[
"Hydroxychloroquine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",... | Hydroxychloroquine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Pazopanib (Compound)
Hydroxychloroquine (Compound) downregulates TES (Gene) and TES (Gene) is downregulated by Pazopanib (Compound)
Hydroxychloroquine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Pazopani... |
DB00580 | DB00682 | 311 | 126 | [
"DDInter1910",
"DDInter1951"
] | Valdecoxib | Warfarin | Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke. | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Moderate | 1 | [
[
[
311,
24,
126
]
],
[
[
311,
63,
663
],
[
663,
23,
126
]
],
[
[
311,
24,
477
],
[
477,
62,
126
]
],
[
[
311,
24,
1017
],
[
1017,
6... | [
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
... | Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a minor interaction that can limit clinical effects when taken with Warfarin
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilost... |
DB00500 | DB09122 | 24 | 1,613 | [
"DDInter1831",
"DDInter1409"
] | Tolmetin | Peginterferon beta-1a | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
24,
24,
1613
]
],
[
[
24,
24,
1274
],
[
1274,
24,
1613
]
],
[
[
24,
1,
831
],
[
831,
24,
1613
]
],
[
[
24,
24,
1383
],
[
1383,
6... | [
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],... | Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Tolmetin (Compound) resembles Indomethacin (Compound) and Indomethacin may cause a moderate interac... |
DB00529 | DB01259 | 789 | 392 | [
"DDInter779",
"DDInter1024"
] | Foscarnet | Lapatinib | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
789,
24,
392
]
],
[
[
789,
21,
28852
],
[
28852,
60,
392
]
],
[
[
789,
23,
112
],
[
112,
23,
392
]
],
[
[
789,
24,
918
],
[
918,
... | [
[
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Foscarnet",
"{u} (Compound) causes {v} (Side Effect)",
"Leukopenia"
],
[
"Leukopenia",
"{u} (Side Effect) is cause... | Foscarnet (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Lapatinib (Compound)
Foscarnet may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lapati... |
DB00533 | DB00877 | 1,416 | 629 | [
"DDInter1613",
"DDInter1678"
] | Rofecoxib | Sirolimus | Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene m... | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Major | 2 | [
[
[
1416,
25,
629
]
],
[
[
1416,
24,
167
],
[
167,
24,
629
]
],
[
[
1416,
63,
1645
],
[
1645,
24,
629
]
],
[
[
1416,
24,
1019
],
[
1019,
... | [
[
[
"Rofecoxib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocort... | Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Me... |
DB00526 | DB08889 | 1,555 | 350 | [
"DDInter1355",
"DDInter299"
] | Oxaliplatin | Carfilzomib | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combi... | Moderate | 1 | [
[
[
1555,
24,
350
]
],
[
[
1555,
24,
833
],
[
833,
1,
350
]
],
[
[
1555,
24,
1270
],
[
1270,
63,
350
]
],
[
[
1555,
63,
482
],
[
482,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lopinavir"
],
[
... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Lopinavir and Lopinavir (Compound) resembles Carfilzomib (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative and Tuberculin purified prote... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.